Discrimination between clinical significant and insignificant prostate cancer with Apparent diffusion coefficient – A systematic review and meta analysis

CURRENT STATUS: UNDER REVISION

BMC Cancer  BMC Series

Hans-Jonas Meyer
Universitat Leipzig
✉ Hans-Jonas.meyer@medizin.uni-Leipzig.de
Corresponding Author
ORCiD: https://orcid.org/0000-0001-8489-706X

Andreas Wienke
Martin-Luther-Universitat Halle-Wittenberg

Alexey Surov
Otto von Guericke Universitat Magdeburg

DOI: 10.21203/rs.3.rs-16729/v1

SUBJECT AREAS
Oncology  Cancer Biology

KEYWORDS
meta analysis, systematic review, prostate cancer, DWI, Gleason score
Abstract
Background Multiparametric MRI has become a corner stone in diagnosis of prostate cancer (PC). Diffusion weighted imaging and the apparent diffusion coefficient (ADC) can be used to reflect tumor microstructure. The present analysis sought to compare ADC values of clinically insignificant with clinical significant PC based upon a large patient sample. Methods MEDLINE library and SCOPUS databases were screened for the associations between ADC and Gleason score in PC up to May 2019. The primary endpoint of the systematic review was the ADC value of PC groups according to Gleason score. In total 27 studies were suitable for the analysis and included into the present study. The included studies comprised a total of 1633 lesions. Results Clinically relevant PCs (Gleason score 7 and higher) were diagnosed in 1078 cases (66.0%) and insignificant PCs (Gleason score 5 and 6) in 555 cases (34.0%). The pooled mean ADC value of the clinically significant PC was 0.86x10-3 mm2/s [95% CI 0.83-0.90] and the pooled mean value of insignificant PC was 1.1 x10-3 mm2/s [95% CI 1.03-1.18]. Clinical significant PC showed lower ADC values compared to non-significant PC. The pooled ADC values of clinically insignificant PCs were no lower than 0.75 ×10-3 mm2/s. This value may be proposed as a threshold for distinguishing clinically significant from insignificant PCs. Conclusions We evaluated the published literature comparing clinical insignificant with clinically prostate cancer in regard of the Apparent diffusion coefficient values derived from magnetic resonance imaging. We identified that the clinically insignificant prostate cancer have lower ADC values than clinically significant, which may aid in tumor noninvasive tumor characterization in clinical routine.

Background
Multiparametric magnetic resonance imaging (mpMRI) has become a corner stone of diagnosis in prostate cancer (PC) in a cost effective and highly accurate manner [1–4]. A great concern in PC treatment is possible over-diagnosing and over-treatment due to very different biological behaviors of PC, discriminated using Gleason score (GS) [5–7]. GS is still one of the most important prognostic features in prostate cancer [6]. So, a cancer with a GS 6 or lower is considered as a clinically insignificant cancer, which will most likely not result in cancer related death. Therefore, it can be treated in some cases with clinical surveillance [5]. However, PC with a GS of 7 and higher is clinically
significant and is associated with tumor related morbidity/mortality [8].

In clinical routine mpMRI is very beneficial due to the high negative predictive value [1]. However, mpMRI can also detect more lesions than conventional diagnostic work flow, which might result in more insignificant cancers [9].

Diffusion-weighted imaging (DWI) is an important sequence of mpMRI. DWI reflects free water movement in tissues [10]. Furthermore, restriction of free water movement in tissues can be quantified by apparent diffusion coefficient (ADC) [10]. ADC is associated with histological features, which restrict diffusion of water molecules, like cell count and protein concentration in the extracellular space [11, 12]. Thus, ADC may aid in discrimination of several tumors. Previously, numerous studies reported that malignant tumors have significantly lower ADC values compared to benign lesions [13, 14].

PC had also lower ADC values in comparison to benign prostatic tissue [15]. Therefore, DWI is an established technique for detection of PC, especially in the peripheral zone [3].

Besides diagnostic potential, DWI/ADC can also aid characterize prostatic tumors. So far, a recent meta-analysis showed that ADC values correlated inversely with GS [16]. In detail, a correlation coefficient of $r = -0.45$ between ADC and GS was reported in all PCs [16]. Furthermore, it was stronger in PC located in the peripheral zone ($r = -0.48$) in comparison to PCs arose in the transitional zone ($r = -0.22$). Presumably, ADC may discriminate low risk PCs from high risk tumors. However, published data above are inconsistent and based on small single center studies.

The purpose of the present systematic review and meta-analysis was to compare ADC values between clinically significant and non-significant PCs according to GS in a large patient sample.

**Methods**

**Data acquisition**

MEDLINE library and SCOPUS databases were screened for the associations between ADC and Gleason score in PC up to May 2019. The paper acquisition is summarized in Fig. 1. The following search words were used: “prostate cancer OR prostatic carcinoma OR prostatic cancer OR prostate carcinoma AND DWI OR diffusion weighted imaging OR ADC OR apparent diffusion
The primary endpoint of the systematic review was the ADC value of PC groups according to Gleason score.

Studies (or subsets of studies) were included, if they satisfied all the following criteria: (1) patients with PC confirmed by histopathology, (2) mpMRI with DWI sequence quantified by ADC values, and (3) reported ADC value according to GS.

Exclusion criteria were (1) systematic review, (2) case reports, (3) treatment prediction or histopathology performed after treatment, (4) non-English language, and (5) experimental (xenograft or animals model) studies.

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used for the analysis [17]. In total 27 studies were suitable for the analysis and included into the present study [18-41].

Quality-assessment

The methodological quality of the acquired studies was independently evaluated by two readers (A.S. and H.J.M.) using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) instrument [42].

Results of QUADAS-2 assessments are shown in Fig. 2.

Statistical analysis

The meta analysis was performed using RevMan 5.3 (2014; Cochrane Collaboration, Copenhagen, Denmark). Heterogeneity was calculated by means of the inconsistency index $I^2$ [43, 44]. Finally, DerSimonian and Laird [45] random-effect models with inverse-variance weights were performed without any further correction.

Results

Of the included 27 studies, 9 (33.3%) were of prospective and 18 of (66.7%) retrospective design. Different 1.5T scanners were used in 7 (25.9%) studies and 3T scanners in 20 (74.1%) studies. In 7 studies (25.9%) an additional endorectal coil was used. In 9 studies (33.3%) a bowel preparation was performed.

In all studies, the diagnosis was confirmed by histopathology. The histopathological diagnosis and scoring of PC was made on specimen after radical prostatectomy in 15 studies (55.6%), in 10 studies
(37.0%) after transrectal ultrasound guided biopsy, and in 2 studies (7.4%) with both techniques. The acquired 27 studies comprised a total of 1633 lesions. Clinically relevant PCs (Gleason score 7 and higher) were diagnosed in 1078 cases (66.0%) and insignificant PCs (Gleason score 5 and 6) in 555 cases (34.0%).

The pooled mean ADC value of the clinically significant PC was $0.86 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 0.83–0.90] and the pooled mean value of insignificant PC was $1.1 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 1.03–1.18]. Figure 3 shows the distribution of ADC values divided in clinically significant and insignificant PC. Thereafter, PCs were divided into subgroups according to the GS as follows: GS 5 and 6 (n = 555, 34.0%), GS 7 (n = 258, 15.8%), GS 8 (n = 42, 2.6%) and GS 9 (n = 30, 1.8%). The pooled mean ADC values of the subgroups were as follows: GS 5 + 6 = $1.1 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 1.03–1.18], GS 7 = $0.87 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 0.80–0.94], and GS 8 and 9 = $0.76 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 0.71–0.82].

Furthermore, the GS 7 group was divided into cancers with a primary GS 3 pattern with a sum of 3 + 4 and those with a primary GS 4 pattern with a sum of 4 + 3. GS 3 + 4 were total 7 studies with 170 lesions. The pooled mean ADC value was $0.91 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 0.82–1.01]. GS 4 + 3 were total 4 studies with 88 lesions. The pooled mean ADC value was $0.80 \times 10^{-3} \text{ mm}^2/\text{s}$ [95% CI 0.69–0.91].

**Discussion**

The present work is the first systematic review and meta-analysis comparing ADC values of clinically significant and insignificant PCs classified according to GS. Because it is based on a large cohort, it provides evident data regarding the quantitative analysis of DWI in distinguishing of different PCs. GS is still one of the most important prognostic factors in PC to stratify patients employing a robust and durable method [6, 46]. So, GS is significantly associated with biochemical free survival [47]. As already mentioned, there is need to discriminate clinically insignificant PCs (GS 6 and lower), which are in almost every cases sufficiently treated with radical prostatectomy, whereas GS 7 and higher cancers are defined as clinically significant with a possibility of recurrence and tumor related death [46]. To predict GS non-invasively by mpMRI might be crucial because it is increasingly used in clinical routine. Thus, more cancers will be detected, which might result in over-diagnosing and over-
treatment, when more clinically insignificant tumors are detected.

As reported previously, DWI/ADC can reflect tissue microstructure in several tumor entities, including PC [11]. In most studies, ADC inversely correlated with cellularity [11]. This is explained by the fact that the extracellular protons are mainly producing the MRI signal. Thus, in cell rich tumors, the extracellular water movement is lowered and correspondingly, the ADC value is also lowered.

Regarding PC, not only cell density is important, but also the glandular structure and formation of the tissue, which is also the most important factor for GS grading [6, 46, 48]. According to the literature, besides cellularity, ADC can also reflect other histopathological features in PC including proliferation index, vascular endothelial expression and hypoxia 1-alpha expression [48, 49]. In fact, it was unambiguously shown that ADC values are positively correlated with amount of glandular lumen with $r = 0.688$ and ADC values are negatively correlated to sole cell count ($r=-0.598$) [48]. Consequently, ongoing research, showed weak to moderate inverse correlations between ADC values and GS, which further strengthened that ADC values are able to reflect tumor microstructure in a non-invasive way with possible translational benefit in daily clinical routine [16].

The present meta-analysis showed that ADC values of different PCs distinct overlapped. However, clinically significant PC defined as PC with GS 7 and higher had lower ADC values than insignificant PCs. Moreover, the pooled ADC values of clinically insignificant PCs were no lower than $0.75 \times 10^{-3}$ mm$^2$/s. Therefore, this value may be proposed as a threshold for distinguishing clinically significant from insignificant PCs. This is the main finding of the present work.

There is recent literature suggesting that GS7 tumors include biological heterogeneous PCs. So far, GS 7 cancers can be estimated as 3 + 4 and 4 + 3 [50–53]. For the first group, the well differentiated cancer pattern is predominant. In contrast, for 4 + 3 lesions, the less differentiated pattern is predominant. This also might reflect different tumor behavior. For example, 4 + 3 cancers are more likely to be tumors with greater pathologic stage, and total tumor volume [50]. Our data corroborate the notion that GS7 cancers are heterogeneous in terms of their ADC values. In fact, GS 3 + 4 tumors had higher ADC values in comparison to GS 4 + 3 cancers. Presumably, ADC values are able to aid
stratify GS 7 cancer, albeit further studies are needed to confirm these results. Interestingly, some previous studies indicated that conventional imaging analysis by PIRADS scoring, a clinical used scoring system to predict the malignancy possibility, is not capable to discriminate between clinical significant and non-significant PC [54]. In PIRADS scoring, only a qualitative assessment based upon DWI, T2-weighted imaging, and contrast enhanced dynamic MRI [3]. ADC values are not quantitatively assessed in this system. Presumably, ADC values might harbor crucial information regarding GS in PC, which is not currently considered in clinical practice. In fact, Pierre et al. suggested that ADC quantification might aid in diagnosing of PC beyond the qualitative DWI assessment [55].

The present meta-analysis has several limitations to address. Firstly, it is mainly comprised of retrospective studies with possible known bias. Secondly, it was not possible to further stratify the patient samples according to tumor localization. Recently, a meta-analysis showed that cancers arising from transitional zone weaker correlated with GS, which might have an influence on the present analysis. Thirdly, we could not divide the patient sample according to biopsy and radical prostatectomy grading. It was shown that both methods might result in slightly different GS. Fourthly, no exact threshold values and sensitivity/specificity could be established for discrimination of clinical significant and non-significant cancers. This reflects one limitation of ADC values caused by variabilities due to hardware including different MRI scanners, sequence parameters, and interreader variability, which hinders to establish clear threshold values for clinical routine. However, as shown, the pooled ADC values of clinically insignificant PCs were no lower than $0.75 \times 10^{-3} \, \text{mm}^2/\text{s}$. Fifthly, our results might be affected by possible publication bias because negative studies, which could not identify an inverse correlation between PC with different GS might not be published.

Clearly, further prospective studies based on large samples are needed to proof and confirm our present results.

Conclusions
Clinical significant PC showed lower ADC values compared to non-significant PC. The pooled ADC values of clinically insignificant PCs were no lower than $0.75 \times 10^{-3} \, \text{mm}^2/\text{s}$. This value may be
proposed as a threshold for distinguishing clinically significant from insignificant PCs. The quantitative assessment of ADC should be included into the stratification of PCs in clinical practice.

**Abbreviations**

mpMRI: multiparametric magnetic resonance imaging

PC :prostate cancer

GS: Gleason score

DWI : Diffusion-weighted imaging

ADC: apparent diffusion coefficient

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QUADAS: Quality Assessment of Diagnostic Accuracy Studies

**Declarations**

**Acknowledgements**: not applicable

**Author Contributions**

Alexey Surov had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Hans-Jonas Meyer, Andreas Wienke, Alexey Surov.

Acquisition of data: Hans-Jonas Meyer, Andreas Wienke

Analysis and interpretation of data: Andreas Wienke, Alexey Surov

Drafting of the manuscript: Hans-Jonas Meyer

Critical revision of the manuscript for important intellectual content: Andreas Wienke, Alexey Surov

Statistical analysis: Andreas Wienke

Obtaining funding: none

Administrative, technical, or material support: none

Supervision: Alexey Surov

Other: None.

**Funding**: None
Availability of data and materials: available on reasonable request

Ethics approval and consent to participate: Not applicable.

Consent for publication: Not applicable.

Competing interests: None to declare

References

1. Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briërs E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017;72(2):250-66.

2. Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815-22.

3. Greer MD, Brown AM, Shih JH, Summers RM, Marko J, Law YM, Sankineni S, George AK, Merino MJ, Pinto PA, Choyke PL, Turkbey B. Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. J Magn Reson Imaging. 2017;45(2):579-85.

4. Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015;68(6):1045-53.
5. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046-55.

6. Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading Am J Surg Pathol. 2016;40(2):244-52.

7. Nunez Bragayrac LA, Murekeyisoni C, Vacchio MJ, Attwood K, Mehedint DC, Mohler JL, Azabdaftari G, Xu B, Kauffman EC. Blinded review of archival radical prostatectomy specimens supports that contemporary Gleason score 6 prostate cancer lacks metastatic potential. Prostate. 2017;77(10):1076-81.

8. Ham WS, Chalfin HJ, Feng Z, Trock BJ, Epstein JI, Cheung C, Humphreys E, Partin AW, Han M. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol. 2017;71(6):907-12.

9. Russo F, Regge D, Armando E, Giannini V, Vignati A, Mazzetti S, Manfredi M, Bollito E, Correale L, Porpiglia F. Detection of prostate cancer index lesions with multiparametric magnetic resonance imaging (mp-MRI) using whole-mount histological sections as the reference standard. BJU Int. 2016;118(1):84-94.

10. Dietrich O, Biffar A, Baur-Melnyk A, Reiser Technical aspects of MR diffusion imaging of the body. Eur J Radiol. 2010;76(3):314-22.

11. Surov A, Meyer HJ, Wienke A. Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget. 2017;8(35):59492-9.

12. Hauge A, Wegner CS, Gaustad JV, Simonsen TG, Andersen LMK, Rofstad EK. Diffusion-weighted MRI-derived ADC values reflect collagen I content in PDX models of uterine
cervical cancer. Oncotarget. 2017;8(62):105682-91.

13. Koontz NA, Wiggins RH 3rd. Differentiation of Benign and Malignant Head and Neck Lesions With Diffusion Tensor Imaging and DWI. AJR Am J Roentgenol. 2017;208(5):1110-5.

14. Suo S, Zhang K, Cao M, Suo X, Hua J, Geng X, Chen J, Zhuang Z, Ji X, Lu Q, Wang H, Xu J. Characterization of breast masses as benign or malignant at 3.0T MRI with whole-lesion histogram analysis of the apparent diffusion coefficient. J Magn Reson Imaging. 2016;43(4):894-902.

15. De Visschere PJ, Vral A, Perletti G, Pattyn E, Praet M, Magri V, Villeirs GM. Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate. Eur Radiol. 2017;27(5):2095-109.

16. Surov A, Meyer HJ, Wienke A. Correlations between Apparent Diffusion Coefficient and Gleason Score in Prostate Cancer: A Systematic Review. Eur Urol Oncol. S2588-9311(18)30214-1.

17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.

18. Bittencourt LK, Barentsz JO, de Miranda LC, Gasparetto EL. Prostate MRI: diffusion-weighted imaging at 1.5T correlates better with prostatectomy Gleason Grades than TRUS-guided biopsies in peripheral zone tumours. Eur Radiol. 2012;22(2):468-75.

19. Caivano R, Rabasco P, Lotumolo A, Cirillo P, D’Antuono F, Zandolino A, Villonio A, Macarini L, Salvatore M, Cammarota A. Comparison between Gleason score and apparent diffusion coefficient obtained from diffusion-weighted imaging of prostate cancer patients. Cancer Invest. 2013;31(9):625-9.

20. Chatterjee A, Bourne RM, Wang S, Devaraj A, Gallan AJ, Antic T, Karczmar GS, Oto A. Diagnosis of Prostate Cancer with Noninvasive Estimation of Prostate Tissue
Composition by Using Hybrid Multidimensional MR Imaging: A Feasibility Study. Radiology. 2018;287(3):864-73.

21. Chung MP, Margolis D, Mesko S, Wang J, Kupelian P, Kamrava M. Correlation of quantitative diffusion-weighted and dynamic contrast-enhanced MRI parameters with prognostic factors in prostate cancer. J Med Imaging Radiat Oncol. 2014;58(5):588-94.

22. Doo KW, Sung DJ, Park BJ, Kim MJ, Cho SB, Oh YW, Ko YH, Yang KS. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI. Eur Radiol. 2012;22(8):1812-9.

23. Faletti R, Battisti G, Discalzi A, Grognardi ML, Martinello S, Oderda M, Gontero P, Bergamasco L, Cassinis MC, Fonio P. Can DW-MRI, with its ADC values, be a reliable predictor of biopsy outcome in patients with suspected prostate cancer? Abdom Radiol (NY).2016;41(5):926-33.

24. Hambrock T, Somford DM, Huisman HJ, van Oort IM, Witjes JA, Hulsbergen-van de Kaa CA, Scheenen T, Barentsz JO. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology. 2011;259(2):453-61.

25. Ibrahiem EI, Mohsen T, Nabeeh AM, Osman Y, Hekal IA, Abou El-Ghar M. DWI-MRI: single, informative, and noninvasive technique for prostate cancer diagnosis. ScientificWorldJournal. 2012;2012:973450.

26. Li L, Margolis DJ, Deng M, Cai J, Yuan L, Feng Z, Min X, Hu Z, Hu D, Liu J, Wang L. Correlation of gleason scores with magnetic resonance diffusion tensor imaging in peripheral zone prostate J Magn Reson Imaging. 2015;42(2):460-7.

27. Li C, Chen M, Wang J, Wang X, Zhang W, Zhang C. Apparent diffusion coefficient values are superior to transrectal ultrasound-guided prostate biopsy for the
assessment of prostate cancer aggressiveness. Acta Radiol. 2017;58(2):232-9.

28. Liu W, Liu XH, Tang W, Gao HB, Zhou BN, Zhou LP. Histogram analysis of stretched-exponential and monoexponential diffusion-weighted imaging models for distinguishing low and intermediate/high gleason scores in prostate carcinoma. J Magn Reson Imaging. 2018;48(2):491-8.

29. Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, Thomas MA. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol. 2012;2012:374805.

30. Park SY, Kim CK, Park JJ, Park BK. Exponential apparent diffusion coefficient in evaluating prostate cancer at 3 T: preliminary experience. Br J Radiol. 2016;89(1058):20150470.

31. Sokmen BK, Sokmen D, Ucar N, Ozkurt H, Simsek A. The correlation between biological activity and diffusion-weighted MR imaging and ADC value in cases with prostate cancer. Arch Ital Urol Androl. 2017;89(4):277-81.

32. Somford DM, Hambrock T, Hulsbergen-van de Kaa CA, Fütterer JJ, van Oort IM, van Basten JP, Karthaus HF, Witjes JA, Barentsz JO. Initial experience with identifying high-grade prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤ 3 + 3 = 6 upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012;47(3):153-8.

33. Suo S, Chen X, Wu L, Zhang X, Yao Q, Fan Y, Wang H, Xu J. Non-Gaussian water diffusion kurtosis imaging of prostate cancer. Magn Reson Imaging. 2014;32(5):421-7.

34. Tian W, Zhang J, Tian F, Shen J, Niu T, He G, Yu H. Correlation of diffusion tensor imaging parameters and Gleason scores of prostate cancer. Exp Ther Med. 2018;15(1):351-6.
35. Turkbey B, Shah VP, Pang Y, Bernardo M, Xu S, Kruecker J, Locklin J, Baccala AA Jr, Rastinehad AR, Merino MJ, Shih JH, Wood BJ, Pinto PA, Choyke PL. Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? Radiology. 2011;258(2):488-95.

36. Uribe CF, Jones EC, Chang SD, Goldenberg SL, Reinsberg SA, Kozlowski P. In vivo 3T and ex vivo 7T diffusion tensor imaging of prostate cancer: Correlation with histology. Magn Reson Imaging. 2015;33(5):577-83.

37. Woo S, Kim SY, Cho JY, Kim SH. Preoperative Evaluation of Prostate Cancer Aggressiveness: Using ADC and ADC Ratio in Determining Gleason Score. AJR Am J Roentgenol. 2016;207(1):114-20.

38. Wu X, Reinikainen P, Vanhanen A, Kapanen M, Vierikko T, Ryymin P, Hyödynmaa S, Kellokumpu-Lehtinen PL. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer. Diagn Interv Imaging. 2017;98(1):63-71.

39. Yağci AB, Ozari N, Aybek Z, Düzcan E. The value of diffusion-weighted MRI for prostate cancer detection and localization. Diagn Interv Radiol. 2011;17(2):130-4.

40. Zhang YD, Wang Q, Wu CJ, Wang XN, Zhang J, Liu H, Liu XS, Shi HB. The histogram analysis of diffusion-weighted intravoxel incoherent motion (IVIM) imaging for differentiating the gleason grade of prostate cancer. Eur Radiol. 2015;25(4):994-1004.

41. Zhang Z, Xu H, Xue Y, Li J, Ye Q. Risk Stratification of Prostate Cancer Using the Combination of Histogram Analysis of Apparent Diffusion Coefficient Across Tumor Diffusion Volume and Clinical Information: A Pilot Study. J Magn Reson Imaging. 2019;49(2):556-64.

42. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-
2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-36.

43. Leeflang MM, Deeks JJ, Gatsionis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149(12):889-97.

44. Zamora J, Abaira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: A software for meta-analysis of test accuracy data. BMC Medical Research Methodology. 2006;6:31.

45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials. 1986;7(3):177-88.

46. Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753-60.

47. Miyake H, Muramaki M, Furukawa J, Tanaka H, Inoue TA, Fujisawa M. Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy. Urol Oncol. 2013;31(8):1511-6.

48. Chatterjee A, Watson G, Myint E, Sved P, McEntee M, Bourne R. Changes in Epithelium, Stroma, and Lumen Space Correlate More Strongly with Gleason Pattern and Are Stronger Predictors of Prostate ADC Changes than Cellularity Metrics. Radiology. 2015;277(3):751-62.

49. Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, Huang Z. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF. NMR Biomed. 31(3):e3884.

50. Huang CC, Kong MX, Zhou M, Rosenkrantz AB, Taneja SS, Melamed J, Deng FM. Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low-risk tumor in radical prostatectomy specimen. Am J Surg Pathol. 2014;38(8):1096-101.

51. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M,
Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: does 3+4=4+3? J Clin Oncol. 2009;27(21):3459-64.

52. Makarov DV, Sanderson H, Partin AW, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4+3 and 3+4 independent of the number of involved cores? J Urol. 2002;167(6):2440-2.

53. Amin A, Partin A, Epstein JI. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol. 2011;186(4):1286-90.

54. Slaoui H, Neuzillet Y, Ghoneim T, Rouanne M, Abdou A, Lugagne-Delpon PM, Scherrer A, Radulescu C, Delancourt C, Molinié V, Lebret T. Gleason Score within Prostate Abnormal Areas Defined by Multiparametric Magnetic Resonance Imaging Did Not Vary According to the PIRADS Score. Urol Int. 2017;99(2):156-61.

55. Pierre T, Cornud F, Colléter L, Beuvon F, Foissac F, Delongchamps NB, Legmann P. Diffusion-weighted imaging of the prostate: should we use quantitative metrics to better characterize focal lesions originating in the peripheral zone? Eur Radiol. 2018;28(5):2236-45.

Figures
Figure 1

PRISMA flow chart. An overview of the paper acquisition. Overall, 27 articles comprising 1633 patients were suitable for the analysis.
QUADAS-2 quality assessment of the included studies. Most studies showed an overall low risk of bias.

| Study or Subgroup | ADC mean | SE | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
|-------------------|----------|----|--------|-------------------|-------------------|
| 1.2.1 Gleason 5 & 6 | 0.91 | 0.07 | 0.9% | 0.91 [0.77, 1.05] |      |
| Cavano 2013a      | 1.48 | 0.02 | 1.0% | 1.48 [1.44, 1.52] |      |
| Cavano 2013b      | 1.19 | 0.03 | 1.0% | 1.19 [1.13, 1.25] |      |
| Chatterjee 2019a  | 0.9 | 0.02 | 1.0% | 0.90 [0.66, 0.94] |      |
| Chung 2014a       | 1.07 | 0.05 | 1.0% | 1.07 [0.97, 1.17] |      |
| Doo 2012a         | 0.87 | 0.03 | 1.0% | 0.87 [0.81, 0.93] |      |
| Falati 2018a      | 0.82 | 0.04 | 1.0% | 0.82 [0.74, 0.90] |      |
| Hambroker 2012a   | 1.3 | 0.06 | 0.9% | 1.30 [1.18, 1.42] |      |
| Ibranovic 2012a   | 1.49 | 0.08 | 0.8% | 1.49 [1.33, 1.65] |      |
| Li 2014a          | 1.11 | 0.02 | 1.0% | 1.11 [1.07, 1.15] |      |
| Li 2017a          | 1.12 | 0.06 | 0.9% | 1.12 [1.00, 1.24] |      |
| Liu 2018a         | 0.84 | 0.02 | 1.0% | 0.84 [0.80, 0.88] |      |
| Nagarajan 2012a   | 1.14 | 0.03 | 1.0% | 1.14 [1.08, 1.20] |      |
| Park 2016a        | 0.97 | 0.06 | 0.9% | 0.97 [0.85, 1.09] |      |
| Sakmen 2013a      | 1.11 | 0.02 | 1.0% | 1.11 [1.07, 1.15] |      |
| Stanford 2012a    | 1.16 | 0.05 | 1.0% | 1.16 [1.06, 1.26] |      |
| Su 2016a          | 0.88 | 0.02 | 1.0% | 0.88 [0.84, 0.92] |      |
| Tian 2018a        | 1.07 | 0.01 | 1.0% | 1.07 [1.05, 1.09] |      |
| Turkbey 2011a     | 1.22 | 0.06 | 0.9% | 1.22 [1.10, 1.34] |      |
| Urbek 2015a       | 1.59 | 0.05 | 1.0% | 1.59 [1.49, 1.69] |      |
| Wu 2016a          | 1.1 | 0.03 | 1.0% | 1.10 [1.04, 1.16] |      |
| Wu 2017a          | 0.77 | 0.03 | 1.0% | 0.77 [0.71, 0.83] |      |
| Yagci 2011a       | 1.18 | 0.16 | 0.9% | 1.18 [0.87, 1.49] |      |
| Zhang 2015a       | 1.5 | 0.06 | 1.0% | 1.50 [1.40, 1.60] |      |
| Zhang Z 2015a     | 0.9 | 0.02 | 1.0% | 0.90 [0.88, 0.94] |      |
| Subtotal (95% CI) |        |    | 23.9% | 1.10 [1.03, 1.18] |      |

Heterogeneity: $I^2 = 0.54$, $Chi^2 = 1234.54$, df = 24 ($P < 0.00001$), $I^2 = 98$

Test for overall effect: $Z = 27.77$ ($P < 0.00001$)
| Study                | Mean ADC | 95% CI  | p-value  |
|---------------------|----------|---------|----------|
| Blichert 2012b      | 0.73     | 0.67, 0.81 | 0.001   |
| Blichert 2012c      | 0.76     | 0.68, 0.83 | 0.002   |
| Blichert 2012d      | 0.54     | 0.46, 0.62 | 0.02    |
| Calace 2015c        | 1.10     | 1.00, 1.20 | 0.001   |
| Calace 2015d        | 0.92     | 0.85, 1.00 | 0.01    |
| Chatzileon 2010b    | 0.89     | 0.83, 0.95 | 0.001   |
| Chatzileon 2010c    | 0.61     | 0.55, 0.67 | 0.001   |
| Chung 2014b         | 1.05     | 0.97, 1.13 | 0.001   |
| Chung 2014c         | 0.89     | 0.82, 0.96 | 0.001   |
| Done 2012b          | 0.78     | 0.70, 0.85 | 0.001   |
| Fasetti 2016b       | 0.74     | 0.66, 0.82 | 0.001   |
| Fasetti 2016c       | 0.68     | 0.60, 0.75 | 0.001   |
| Fasetti 2016d       | 0.63     | 0.55, 0.71 | 0.001   |
| Glazer 2017         | 0.81     | 0.75, 0.87 | 0.001   |
| Hambrock 2012b      | 1.07     | 1.00, 1.15 | 0.001   |
| Hambrock 2012c      | 0.94     | 0.88, 1.01 | 0.001   |
| Ibaraki 2013b       | 1.05     | 0.98, 1.13 | 0.001   |
| Li 2014a            | 0.98     | 0.91, 1.05 | 0.001   |
| Li 2014b            | 0.91     | 0.84, 0.98 | 0.001   |
| Li 2014c            | 0.91     | 0.84, 0.98 | 0.001   |
| Li 2017b            | 1.12     | 1.05, 1.20 | 0.001   |
| Liu 2019b           | 0.67     | 0.60, 0.74 | 0.001   |
| Nagareng 2012b      | 0.98     | 0.92, 1.05 | 0.001   |
| Natarajan 2012c     | 0.82     | 0.74, 0.90 | 0.001   |
| Park 2016b          | 0.64     | 0.57, 0.71 | 0.001   |
| Park 2016c          | 0.64     | 0.57, 0.71 | 0.001   |
| Park 2016d          | 0.64     | 0.57, 0.71 | 0.001   |
| Sokmen 2013b        | 0.94     | 0.88, 1.00 | 0.001   |
| Sokmen 2013c        | 0.86     | 0.79, 0.93 | 0.001   |
| Sokmen 2013d        | 0.71     | 0.64, 0.78 | 0.001   |
| Sumbord 2012b       | 0.98     | 0.90, 1.05 | 0.001   |
| Spr 2015b           | 0.81     | 0.74, 0.88 | 0.001   |
| Sun 2016b           | 0.79     | 0.72, 0.86 | 0.001   |
| Sun 2016c           | 0.79     | 0.72, 0.86 | 0.001   |
| Tarr 2018b          | 0.96     | 0.90, 1.02 | 0.001   |
| Tarr 2018c          | 0.62     | 0.55, 0.69 | 0.001   |
| Turlbay 2011b       | 0.98     | 0.91, 1.05 | 0.001   |
| Turlbay 2011c       | 0.90     | 0.83, 0.97 | 0.001   |
| Turlbay 2011d       | 0.90     | 0.83, 0.97 | 0.001   |
| Uhrbe 2015b         | 1.41     | 1.35, 1.47 | 0.001   |
| Wu 2016b            | 0.96     | 0.89, 1.03 | 0.001   |
| Wu 2017b            | 0.96     | 0.89, 1.03 | 0.001   |
| Yagci 2011b         | 1.05     | 1.00, 1.11 | 0.001   |
| Yagci 2011c         | 0.89     | 0.82, 0.96 | 0.001   |
| Zhang 2016b         | 1.27     | 1.20, 1.34 | 0.001   |
| Zhang 2016c         | 0.96     | 0.89, 1.03 | 0.001   |

Heterogeneity: I² = 0.0%, Q=2, p=0.99 (I² = 0.0, p = 0.99)
Test for overall effect: Z = 4.88 (p < 0.0001)
Figure 3

a. Forrest plots of the mean apparent diffusion coefficients of clinical insignificant PC comprising Gleason score 5 and 6. The pooled mean ADC value was $1.10 \times 10^{-3}$ mm²/s [95% CI 1.03-1.18]. b. Forrest plots of the mean apparent diffusion coefficients of clinically significant PC comprising Gleason score 7 and higher. The pooled mean ADC value was $0.96 \times 10^{-3}$ mm²/s [95% CI 0.83-0.90].
a. Forrest plots of the mean apparent diffusion coefficients of PC with Gleason score 7. The pooled mean ADC value was $0.87 \times 10^{-3}$ mm$^2$/s [95% CI 0.80-0.94]. b. Forrest plots of the mean apparent diffusion coefficients of PC with Gleason score 8 and higher. The pooled mean ADC value was $0.76 \times 10^{-3}$ mm$^2$/s [95% CI 0.71-0.82]. c. Box plots of the mean ADC values of clinical insignificant comprising Gleason score 5 and 6, Gleason score 7 and Gleason score 8 and 9 PC groups. There is a clear trend for higher Gleason score PC to have lower ADC values.

Figure 4
1.2.4 Gleason 3+4

|                | $p$   | $95\% CI$  | $I^2$ | Test for overall effect |
|----------------|-------|------------|-------|-------------------------|
| Bittencourt 2012b | 0.75  | 0.66, 0.81 | 0.9%  |
| Caivano 2013c    | 1.1   | 1.02, 1.10 | 1.0%  |
| Falez 2016b      | 0.74  | 0.70, 0.78 | 0.8%  |
| Hartsock 2012b   | 1.07  | 0.93, 1.21 | 1.0%  |
| Li 2014b         | 0.96  | 0.94, 1.02 | 1.0%  |
| Nagaejan 2012b   | 0.96  | 0.94, 1.02 | 1.0%  |
| Wu 2017b         | 0.83  | 0.79, 0.87 | 1.0%  |
| Subtotal (95% CI)| 0.81  | 0.82, 1.01 | 6.5%  |

Heterogeneity: $Tau^2 = 0.02$, $Chi^2 = 1.55$, df = 6 ($P < 0.00001$), $I^2 = 35$
Test for overall effect: $Z = 16.24$ ($P < 0.00001$)

1.2.5 Gleason 4+3

|                | $p$   | $95\% CI$  | $I^2$ | Test for overall effect |
|----------------|-------|------------|-------|-------------------------|
| Bittencourt 2012c | 0.78  | 0.68, 0.88 | 0.9%  |
| Fallati 2014c    | 0.68  | 0.62, 0.74 | 0.9%  |
| Li 2014c         | 0.91  | 0.97, 0.95 | 1.0%  |
| Nagarajan 2012c  | 0.83  | 0.77, 0.89 | 0.9%  |
| Subtotal (95% CI)| 0.80  | 0.69, 0.91 | 3.8%  |

Heterogeneity: $Tau^2 = 0.01$, $Chi^2 = 41.97$, df = 3 ($P < 0.00001$), $I^2 = 93$
Test for overall effect: $Z = 14.27$ ($P < 0.00001$)
Figure 5

a. Forrest plots of the mean apparent diffusion coefficients of PC with Gleason score 3+4. The pooled mean ADC value was 0.91 x10-3 mm²/s [95% CI 0.82-1.01]. b. Forrest plots of the mean apparent diffusion coefficients of PC with Gleason score 4+3. The pooled mean ADC value was 0.80 x10-3 mm²/s [95% CI 0.69-0.91]. c. Box plots of the mean ADC values of Gleason score 3+4 and Gleason score 4+3. Gleason 4+3 PC have lower ADC values than Gleason score 3+4.